Drug Trial Radar · NCT00196326
Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive
Last checked: Nov 19, 2026Latest source record: Nov 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,235
Actual
Start
Jun 2005
Primary completion
Jun 2007
Study completion Jun 2007
Sponsor
- Lead sponsor
- Duramed ResearchIndustry
- Sponsor type
- Industry
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.
Conditions
- Contraception
Interventions
DR-1011Drug
Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" PregnancyTime frame: up to one year
- Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining "On Drug" PregnancyTime frame: up to one year
Locations
55 sites in 1 country. Site status is shown where the registry gives one.
Duramed Investigational Site
Huntsville, Alabama
Duramed Investigational Site
Phoenix, Arizona
Duramed Investigational Site
Phoenix, Arizona
Duramed Investigational Site
Phoenix, Arizona
Duramed Investigational Site
Tucson, Arizona
Duramed Investigational Site
San Diego, California
Duramed Investigational Site
San Diego, California
Duramed Investigational Site
Colorado Springs, Colorado
Duramed Investigational Site
Colorado Springs, Colorado
Duramed Investigational Site
Denver, Colorado
Duramed Investigational Site
New London, Connecticut
Duramed Investigational Site
Coral Cables, Florida
Duramed Investigational Site
Hollywood, Florida
Duramed Investigational Site
Jacksonville, Florida
Duramed Investigational Site
Leesburg, Florida
Duramed Investigational Site
Miami, Florida
Duramed Investigational Site
Palm Springs, Florida
Duramed Investigational Site
Sarasota, Florida
Duramed Investigational Site
Tampa, Florida
Duramed Investigational Site
Decatur, Georgia
Duramed Investigational Site
Douglasville, Georgia
Duramed Investigational Site
Boise, Idaho
Duramed Investigational Site
Chicago, Illinois
Duramed Investigational Site
Shawnee Mission, Kansas
Duramed Investigational Site
Topeka, Kansas
Duramed Investigational Site
Louisville, Kentucky
Duramed Investigational Site
Kansas City, Missouri
Duramed Investigational Site
St Louis, Missouri
Duramed Investigational Site
Lawrenceville, New Jersey
Duramed Investigational Site
Moorestown, New Jersey
Duramed Investigational Site
New Brunswick, New Jersey
Duramed Investigational Site
Rochester, New York
Duramed Investigational Site
Charlotte, North Carolina
Duramed Investigational Site
Wilmington, North Carolina
Duramed Investigational Site
Winston-Salem, North Carolina
Duramed Investigational Site
Columbus, Ohio
Duramed Investigational Site
Columbus, Ohio
Duramed Investigational Site
Oklahoma City, Oklahoma
Duramed Investigational Site
Medford, Oregon
Duramed Investigational Site
Philadelphia, Pennsylvania
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.